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Edited by Hans EklundAbstract Ribonuclease A (RNase A) dimers have been recently
found to be endowed with some of the special, i.e., non-catalytic
biological activities of RNases, such as antitumor and aspermat-
ogenic activities. These activities have been so far attributed to
RNases which can escape the neutralizing action of the cytosolic
RNase inhibitor (cRI). However, when the interactions of the
two cytotoxic RNase A dimers with cRI were investigated in a
quantitative fashion and at the molecular level, the dimers were
found to bind cRI with high aﬃnity and to form tight complexes.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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More than 40 years ago Crestﬁeld et al. [1] described the
association of ribonuclease A (RNase A) into active dimers
upon lyophilization from acetic acid solutions. They readily
hinted that the mechanism for formation of a dimeric RNase
A was based on the dissociation of the N-terminal arm from
an RNase monomer followed by its association on another
monomer in which the same N-terminal arm had been
displaced [2].
Few years after their ﬁrst elegant experiments on dimeric
RNase A, Fruchter and Crestﬁeld [3] discovered that, upon
ion-exchange chromatography, dimeric RNase A could be sep-
arated into a minor and a major component that were found to
be in a rather invariable ratio of 1:4, but no structural or func-
tional diﬀerences were detected between these two fractions.Abbreviations: RNase A, ribonuclease A; AA-NS and AA-CS, RNase
A dimers with N-terminal and C-terminal swap, respectively; BS-R-
Nase, bovine seminal RNase; cRI, cytosolic RNase inhibitor; Poly(C),
poly(cytidylic acid); CpA, cytidylyl(30 ﬁ 50)adenosine; Mes, 2-(N-
morpholino)ethanesulfonic acid; Mops, 3-(N-morpholino)propane-
sulfonic acid; p-HMB, p-hydroxymercuribenzoate; PDB, protein data
bank
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doi:10.1016/j.febslet.2005.03.087Much later, the investigation of the oligomerization of
RNase A by lyophilization from acetic acid was resumed by
Libonati and co-workers [4,5] and the 3D structure of a di-
meric RNase A with N-terminal swap was elucidated by Eisen-
berg and co-workers [6]. The existence of two isoforms of
dimeric RNase A was then conﬁrmed and structural and func-
tional diﬀerences were reported between the two dimers [7,8].
This led to identify the 3D structure [6] of the RNase A dimer
with N-terminal swap as that of the minor dimer [8].
Later, Liu et al. [9] determined the three-dimensional struc-
ture of the major RNase A dimer. They found that also in this
dimer the two subunits swapped terminal arms, but surpris-
ingly the swapped segments were C-terminal in the protomer
sequence.
Thus, upon lyophilization from acetic acid solutions sub-
stantial fractions of RNase A undergo diﬀerent types of asso-
ciation into dimers: dimers with N-terminal swap, henceforth
termed AA-NS, and dimers with C-terminal swap termed
AA-CS. Recent reports have shown that by lyophilization in
the conditions described above RNase A associates also into
structurally diﬀerent types of trimers and tetramers [7], and
that association of RNase A can also occur in various media
and at various temperatures, without resorting to lyophiliza-
tion [10,11].
The two dimeric forms of RNase A have since gained an in-
creased attention as prototypes of both domain-swapped olig-
omers and in vitro protein aggregates (see [12,13] for reviews).
Recently, the RNase A dimers have been found to exert in vi-
tro RNase ‘‘special’’ activities, which are distinct, but depen-
dent upon, their ribonucleolytic activity, such as a cytotoxic
action [14]. As these activities have in general been attributed
to RNases with the ability to evade inhibition by the cytosolic
RNase inhibitor (cRI) [15–19], these ﬁndings have been ex-
plained with the hypothesis that the RNase A dimers are resis-
tant to inhibition by the cytosolic inhibitor, due to their
dimeric structure [13]. One of the most cytotoxic RNases, bo-
vine seminal RNase (BS-RNase), is indeed a dimeric RNase,
and is not inhibited by cRI [20]. However, preliminary enzy-
matic assays, carried out in the presence of cRI, have suggested
that the RNase A dimers are inhibited by the cytosolic
inhibitor [8].
The cRI is a modular 50 kDa protein, found in all mamma-
lian cells investigated [21,22], made up of a series of leucine-
rich repeats organized in a horseshoe structure which stronglyblished by Elsevier B.V. All rights reserved.
Fig. 1. The X-ray structure of the complex of cRI (yellow) with RNase
A (green) [23]. The picture was generated using the programs
MOLSCRIPT [46] and Raster3D [47].
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the mammalian RNase superfamily [24]. The most cytotoxic
ribonucleases, namely BS-RNase from seminal vesicles and
onconase [25], are totally resistant to cRI [26]. Onconase is
an amphibian RNase [27], hence it may not be surprising that
it is not recognized by cRI, a mammalian molecule absent in
amphibia; BS-RNase is a dimeric RNase, which as a dimer
cannot ﬁt in the horseshoe cavity of cRI. It has been found
that the cytotoxic activity of some RNases is decreased toward
cells engineered to overexpress cRI [28], whereas cells in which
expression of cRI has been deleted become more sensitive to
cytotoxic RNases [29].
The apparent contrast between the ability of the RNase di-
mers to exert special RNase bioactivities [13,14], and their re-
ported sensitivity to inhibition by the cytosolic inhibitor [8] has
prompted us to investigate in detail the interactions of cRI
with RNase A dimers, to evaluate also quantitatively such
interactions, and to study through modeling their structural
features.2. Materials and methods
2.1. Proteins and substrates
Bovine pancreatic RNase A (type XII-A), poly(cytidylic acid)
(Poly(C)), and cytidylyl(30 ﬁ 5 0)adenosine (CpA) were purchased from
Sigma. Dimers of RNase A were obtained as previously described [7,8].
Angiogenin was a kind gift of Dr. R. Shapiro (Center of Biophysical
and Biochemical Sciences and Medicine, Harvard Medical School,
Boston, MA, USA). The cRI was purchased from Promega; the con-
centration of stock solutions was checked by inhibition assays (in trip-
licate) of RNase A activity with Poly(C) as a substrate. Brieﬂy, 1 pmol
of RNase A was mixed with an aliquot of cRI solution (about
0.5 pmol, based on the concentration given by the manufacturer) in
1 ml of reaction mixture and assayed in comparison with RNase A
(1 nM) alone. Assuming a 1:1 stoichiometry, a 50% inhibition value
was expected. The concentration of cRI was ﬁnally estimated from
the ratio between the measured and the expected inhibition value.The concentration of both RNase A dimers (relative to monomeric
subunit) was calculated by using the extinction coeﬃcient of native
monomeric RNase A, i.e., e278 = 9800 M
1 cm1; for angiogenin an
e280 = 12 500 M
1 cm1 was used. The pH of all samples was measured
before each measurement, at 25 C, with a Radiometer pHmeter
(model PHM93).
2.2. RNase activity assay and inhibition of RNase A dimers by the
cytosolic ribonuclease inhibitor
RNase activity was measured spectrophotometrically by a modiﬁca-
tion of a standard assay [30] with CpA as a substrate. The substrate
(50 lM), dissolved in 0.1 M 2-(N-morpholino)ethanesulfonic acid
(Mes) buﬀer, pH 6.0, containing 0.1 M NaCl and RNase-free bovine
serum albumin (10 lg/ml), was pre-equilibrated at 25 C. When its
absorbance at 286 nm was stable, the reaction was initiated by addition
of enzyme at a ﬁnal concentration of 2.5 nM (relative to monomeric
subunit). After 2 min, an aliquot of cRI (5 nM) was added and its eﬀect
on RNase activity was monitored for about 2 min. To neutralize the
inhibitory action of cRI, an aliquot of p-hydroxymercuribenzoate (p-
HMB) was added to a ﬁnal concentration of 43 lM, and RNase activ-
ity was again recorded. Enzyme units were calculated as change in
absorbance at 286 nm per min · 103. Speciﬁc activity was deﬁned as
units/nmol of monomeric RNase subunit.2.3. Determination of binding parameters of RNase A dimers for cRI
The kinetic parameters of inhibition of RNase A dimers by cRI were
determined following a modiﬁcation of previously described proce-
dures [31–33]. Given the similarity and the composite nature of the ac-
tive site regions of the dimers, all determinations were based on
the assumption that both monomeric subunits of each dimer were
enzymatically active and that each of them bound cRI with the same
aﬃnity.
The apparent second-order rate constants for association of cRI
with each RNase A dimer (kon) were measured by examining the com-
petition for binding to cRI between each RNase A dimer and human
angiogenin. Brieﬂy, RNase A dimers (1 nM, relative to monomeric
subunit) were mixed with angiogenin (0.5 nM) at 25 C in 0.1 M 3-
(N-morpholino)propanesulfonic acid (Mops), pH 7.5, containing
0.1 M NaCl. After addition of cRI (1 nM), the ribonucleolytic activity
measured with Poly(C) as a substrate (100 mM) was that of each free
RNase A dimer, as angiogenin does not degrade Poly(C) under the as-
say conditions [34]. Absorbance increases, due to substrate cleavage,
were monitored at 260 nm as a function of time with a Varian Cary
1E spectrophotometer, equipped with a temperature controller. All as-
says were performed in triplicate at 25 C.
For each RNase A dimer, the kon,D value was then calculated by
using the equation (modiﬁed from [31])
kon;D ¼ kon;A lnð½M TD=½M FDÞ= lnð½AT=½AFÞ;
where kon,A is the apparent second-order rate constant for association
of cRI with angiogenin (1.8 · l08 M1 s1) [32] and [M]TD, [M]FD,
[A]T, [A]F are the concentrations of: monomeric subunit of total di-
mer, monomeric subunit of free dimer, total angiogenin, and free
angiogenin, respectively. The dissociation rate constants of both
RNase A dimers (koﬀ) were determined by ﬁrst forming each cRI–di-
mer complex, then adding a large excess of angiogenin to act as a
scavenger for free cRI and subsequently assaying for free RNase A
dimers, released from the complex as a function of time. Brieﬂy,
RNase A dimers (0.1 lM, relative to monomeric subunit) were pre-
incubated with cRI (0.3 lM) for 40 min at 25 C in 150 lL of
0.1 M Mops, pH 7.5, containing 0.1 M NaCl and 2 mM DTT. Angio-
genin (15 lM) was then added as scavenger for any free cRI dissoci-
ating from cRI–dimer complexes, and the mixture was incubated at
25 C. At various time intervals, aliquots (containing about 0.5 nmol
of monomeric subunit of each dimer) were removed and assayed for
activity in triplicate by using the Poly(C) assay, as described. For
both cRI–dimer complexes, about 80–90% of the dissociation process
was followed and the koﬀ values were determined from plots of
ln(1  [M]/[M0]) versus time, where [M] and [M0] are the concentra-
tions of the monomeric subunit of each dimer at times t and t0,
respectively. Plots were obtained by linear regression (r2 = 0.98) using
10–15 time points in the time range 0–220 min for AA-CS and 0–
130 min for AA-NS. During the experiments, both dimers do not dis-
sociate into monomers [8].
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To analyze complex formation between the cytosolic inhibitor and
RNase A dimers, a twofold excess of the cytosolic inhibitor
(40 pmol) was incubated with native RNase A (20 pmol) and each
dimer (20 pmol of monomeric subunit) for 15 min at 25 C in
15 ll of 0.1 M Na phosphate buﬀer, pH 6.55, containing 2 mM
dithiothreitol. Each sample was then added to 15 ll of 125 mM
Tris–HCl, pH 6.8, containing 15% glycerol, 0.02% xylene cyanol
and 0.02% bromophenol blue. Electrophoresis was run on 10% poly-
acrylamide gel under the conditions described by Laemmli [35], but
with no sodium dodecyl-sulfate (SDS) as a denaturant in the run-
ning buﬀer (0.04 M Tris–acetate, 1 mM EDTA, pH 8.0) and in
the polyacrylamide gel.1 2  3 4  5 6
time (min)
Fig. 2. Eﬀects of the cytosolic RNase inhibitor on the ribonuclease
activity toward CpA of AA-CS and AA-NS dimers of RNase A. The
addition of dimer (2.5 nM, relative to monomeric subunit), cRI
(5 nM), and p-HMB (43 lM) is indicated by an arrow. See text for
details.2.5. Molecular graphics analyses
Plausible three-dimensional models of the complexes between cRI
and RNase A dimers were generated by molecular modeling using
the X-ray structures of AA-CS (protein data bank (PDB) code
1F0V), of AA-NS (PDB code 1A2W) and of the complex between
cRI and RNase A (PDB code 1DFJ). The models were built by assum-
ing that the interactions between each subunit of the two RNase A di-
mers and cRI closely resemble those found in the complex of cRI with
RNase A. Accordingly, the main body (residues 25–110) of RNase A
structure of the cRI/RNase A complex was superimposed to each sub-
unit of both dimers. Superimpositions and molecular graphics analyses
were performed using the program ‘‘O’’ [36].3. Results
3.1. Inhibition of enzymic activity of RNase A dimers by the cRI
A preliminary investigation [8] indicated that both dimers
are inhibited by the cRI. With the aim to perform a systematic
analysis, with indications on the reversibility of the inhibition,
and the formation of cRI–dimer complexes, the following
experiments were performed.
The RNase activity of the two dimers was ﬁrst measured in
comparison with that of the parent RNase A monomer with
CpA as a substrate. The speciﬁc activities of AA-CS and
AA-NS (units/nmol of monomer) were found to be
1.48 ± 0.10 and 1.40 ± 0.08, respectively, about threefold lower
than that of native RNase A (4.9 ± 0.32 units/nmol). Fig. 2
shows a typical inhibition assay. In the presence of a twofold
excess of cRI per mol of monomeric subunit, the RNase activ-
ity of both AA-CS and AA-NS was found to be totally inhib-
ited. The inhibitory eﬀect of cRI was completely reversed when
a large excess of the thiol reagent p-HMB, a known denaturant
of cRI [37], was added to the reaction mixture. This conﬁrmed
that the absence of RNase activity was indeed due to the inhib-
itory action of cRI, and that both AA-NS and AA-CS are fully
inhibited by cRI. Moreover, it should be noted that the speciﬁc
activity values of either dimer after addition of p-HMB to theTable 1
Binding parameters of RNase A dimers (relative to monomeric unit) for cR
Ribonuclease (kon)
a (M1 s1) (koﬀ)
b (s
AA-NS 4.7 ± 0.4 · 108 2.4 ± 0.1
AA-CS 11.3 ± 1.2 · 108 1.3 ± 0.3
RNase A 3.4 · 108 1.5 · 10
Angiogenin 1.8 · 108 1.3 · 10
aDetermined in assays performed in triplicate, at pH 7.5, 25 C, with angiog
bDetermined in assays performed in triplicate, at pH 7.5, 25 C, with angiogreaction mixture (1.42 ± 0.11, for AA-CS; 1.37 ± 0.09, for AA-
NS) were very similar to those observed in the absence of cRI
(see above). Given that p-HMB in control assays had no eﬀect
on the activities of both native and dimeric RNase A, this
observation suggests that both dimers do not dissociate into
RNase A monomers upon binding with cRI, or when the com-
plexes between cRI and dimers are dissociated by the action of
p-HMB. In fact, in case of dissociation into monomers the
activity values should have been much higher, i.e., about
5 units/nmol of monomer.
3.2. The interactions of RNase A dimers with the cRI
Binding of cRI to RNase A dimers was studied by determin-
ing the association and dissociation rate constants for the com-
plexes formed between cRI and AA-NS or AA-CS (see Section
2). This led to the determination of the dissociation constants
(Kd) of the complexes. The association rate constants (kon)
were determined in a competition assay of each dimer with
angiogenin, an RNase whose very tight binding to cRI (see Ta-
ble 1) has been well characterized [32]. Also, the dissociation
rate constants (koﬀ) were determined using angiogenin, but
as a scavenger for free cRI dissociating from preformed di-
mer–cRI complexes. It must be noticed that in both assays,
using angiogenin as a competitor or a scavenger, Poly(C)
was used as a substrate, given that angiogenin does not cleave
Poly(C) at a detectable rate [34]. The values of Kd (relative to
the monomeric functional subunit of each dimer, see Table 1)
were found to be similar for the two dimers, and indicative of aI compared with those of native RNase A and angiogenin
1) Kd (M) Reference
· 104 5.3 · 1013 This work
· 104 1.1 · 1013 This work
5 4.4 · 1014 [32]
7 7.1 · 1016 [32]
enin as a competitor and Poly(C) as a substrate.
enin as a scavenger and Poly(C) as a substrate.
Fig. 3. Electrophoresis on polyacrylamide gel in non-denaturing
conditions of AA-NS and AA-CS dimers of RNase A complexed
with the cytosolic RNase inhibitor (cRI). Lanes 1 and 5: free cRI
(40 pmol) as a standard; lane 2: complex of cRI (40 pmol) with native,
monomeric RNase A (20 pmol); lanes 3 and 4: complexes of cRI
(40 pmol) with AA-NS and AA-CS dimers (20 pmol of monomeric
subunit), respectively.
Fig. 4. Theoretical models of the complexes of cRI (in yellow) with BS-RNase
(PDB code 1A2W) (C). See text for details.
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AA-NS.
Complex formation between RNase A dimers and cRI was
investigated at the molecular level by electrophoresis (see
Fig. 3) on polyacrylamide gels at pH 8.0 of samples of dimers
incubated with an excess of inhibitor. As controls, free cRI and
cRI complexed to native, monomeric RNase A were run in the
same gels. Under these experimental conditions, free RNases
do not enter the gel because of their positive net charge. As
shown in Fig. 3, bound cRI (lane 2) has a lower electrophoretic
mobility than free cRI (lanes 1 and 5), as expected both for the
decrease of negative net charge, due to the bound, strongly cat-
ionic RNase A, and the increased molecular size of the com-
plex. The cRI–AA-NS and cRI–AA-CS complexes were
found to have much lower mobilities, compared to those of
free cRI and of the cRI–RNase A complex. These ﬁndings
are in agreement with an additional decrease of negative
charge and an increase of molecular size in cRI–dimer com-
plexes. These results are in line with the observation made(PDB code 1BSR) [48] (A), AA-CS (PDB code 1F0V) (B), and AA-NS
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that cRI binds both RNase A dimers engendering full inhibi-
tion of the dimers catalytic activity while the dimers maintain
their dimeric structure and do not dissociate into monomers
upon binding with the inhibitor. It should be noted that the re-
sults described here disprove our earlier hypothesis [8], i.e.,
that the inactivation of the dimers could be due to their disso-
ciation caused by the interaction with cRI.
To provide a structural perspective of the complexes be-
tween cRI and the RNase A dimers, the structures of the
complexes of cRI with RNase A dimers and naturally, cova-
lently dimeric BS-RNase were modeled (see Fig. 4) using as a
template the complex [38] of cRI with monomeric RNase A.
As previously reported by Kobe and Deisenhofer [38], bind-
ing of cRI to one subunit of BS-RNase engenders very severe
steric clashes (Fig. 4A), and prevents the formation of the
complex. Consistently with the data presented above on
AA-CS inhibition by cRI and electrophoresis analysis, in
the structure of an AA-CS/cRI complex (Fig. 4B), two cRI
molecules can readily be accommodated on the AA-CS dimer.
On the other hand, the shape of AA-NS would appear to be
incompatible with the binding of cRI (Fig. 4C). For binding
of cRI to one subunit only minor conformational shifts
should occur. However, AA-NS does not possess a strict two-
fold symmetry, thus, binding of a second molecule of cRI
would engender more severe steric clashes. These would occur
between the inhibitor (residues 144–155, 169–184, and 201–
212) and the dimer (residues 49–79 and 105–110). Given that
both AA-NS and AA-CS bind to cRI with very similar aﬃn-
ities and that the formation of full complexes was shown to
occur for both dimers, it could only be surmised that the
apparent hindrance between AA-NS and cRI can be mini-
mized by a conformational change(s) in the inhibitor and/or
the dimer. Recently, a signiﬁcant degree of ﬂexibility in the
AA-NS dimer has been demonstrated by molecular dynamics
study [39].4. Discussion
The results presented above provide a conclusive evidence
that cRI is an inhibitor of RNase A dimers. Hence, they do
not support the hypothesis recently advanced [13] to explain
the cytotoxic action of the RNase A dimers, i.e., that their di-
meric structure prevents these molecules from interacting with
cRI. The strong binding of both AA-CS and AA-NS dimers to
cRI (see Table 1) is also in contrast with the widely accepted
postulate [17,18,40–42] that the cytotoxic activity of a ribonu-
clease molecule relies on its ability to evade the cRI.
Thus, although RNase A dimers share with seminal RNase
both a dimeric structure and the ability to exert special RNase
bioactions, this ability cannot be related to a hypothetical
capacity of RNase A dimers to evade the inhibitory, poten-
tially neutralizing action of the cytosolic inhibitor. When sem-
inal RNase is dissociated into catalytically active monomers, it
is neutralized by the cytosolic inhibitor and is deprived of its
special bioactions [43]. When instead RNase A is dimerized,
it does acquire new special bioactions, but maintains its high
aﬃnity for the cytosolic inhibitor.
The special bioactions of some RNases of the RNase A
superfamily have received a great attention in many years of
experimental work; but no conclusive description has beengiven to the molecular basis of these bioactions, with the
exception that to exercise them RNases must preserve their
ribonucleolytic activity. The results described above may draw
our attention to new directions of investigation. While they do
not provide new positive clues on the molecular basis of an
RNase special bioactions, they indicate that the capacity of
the RNase to evade the neutralizing action of the cytosolic
inhibitor cannot be considered as the main, or certainly not
the only basis for such actions.
It should be noted that these results are in line with previous
results that indicate that RNases engineered to acquire some
special bioactions do so while maintaining their aﬃnity for
the cytosolic inhibitor [44,45]. Recently, it has been shown that
RNases with no special bioactions do not acquire any new bio-
actions when tested on cells in which the cRI has been totally
silenced [29].
Thus, investigations should be directed to new directions
to determine the molecular basis for the special bioactions
of an RNase. It has been established that (i) catalytically
inactivated RNases do not have special bioactions; hence
(ii) these actions involve the degradation of, or the cleavage
of speciﬁc phosphodiester bonds in, some cellular RNA; on
the other hand (iii) the cell compartment of RNA is cyto-
solic, just as that of cRI. At present, no clear evidence is
available concerning extracellular and intracellular steps in
the antitumor action of RNase A dimers. However, it can
be surmised that the positive electrostatic potential of RNase
A dimers, which is stronger than that of monomeric RNase
A [8,13], could aﬀect the interactions of the dimers both with
the polyanionic cell surface and the intracellular membranes.
These features would favor their endocytosis and their intra-
cellular itinerary. Therefore, it can be proposed that, albeit
small, a fraction of either dimer can evade, soon after it en-
ters the cytosol, the neutralizing action of cRI; this would
lead to cytotoxicity of the dimers as degradation of cytosolic,
vital RNA(s) would have a deleterious eﬀect on cell viability.
It should be added that RNA fragments have been reported
to counteract the inhibitory action of cRI [15]. Thus, a pos-
sible conclusion is that RNases with special bioactions are
RNases capable of entering the cytosolic compartment. It
may happen that some of them, such as seminal RNase,
are also capable of escaping the neutralizing action of the
cytosolic inhibitor, as shown by the more powerful cytotoxic
activity of BS-RNase, compared to that of either dimer of
RNase A.
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